Retapamulin

瑞他帕林

Report date: 2022/08/16 14:33:01
NME

Base Information

Drug NameRetapamulin
Drug Alias Name热他莫林retapamulinumretapamulina瑞他姆林瑞他莫林 +[9] 
ClassificationSmall molecules > Heterocyclic drugs > Antibiotics
Mechanisms of Action50S ribosomal subunit inhibitorsProtein biosynthesis inhibitors
Targets50S ribosomal subunit
Therapy Area/IndicationsSkin Diseases, BacterialImpetigoStaphylococcal Skin Infections +[4] 
Global Approved IndicationsImpetigoStaphylococcal Skin Infections
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2007/04/12
Country/TerritoryCanadaUnited StatesPoland +[16] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaDiscontinued
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline Inc
Inactive CompaniesStiefel LaboratoriesAlmirall LlcGlaxosmithkline Plc +[4] 
Active IndicationsStaphylococcal Skin Infections
Inactive IndicationsSkin Diseases, BacterialImpetigoBacterial Infections

Other Information

ATC CodeD06AX13
Related LinksWikipediaDrugBankKEGG